Parasites, Hosts and Diseases

The Korea Society for Parasitology and Tropical Medicine (대한기생충학·열대의학회)
권호 표지
DOI QR코드

DOI QR Code

Protective and Anti-Pathology Effects of Sm Fructose-1,6-Bisphosphate Aldolase-Based DNA Vaccine against Schistosoma mansoni by Changing Route of Injection

  • Saber, Mohamed (Biochemistry Department, Theodor Bilharz Research Institute) ;
  • Diab, Tarek (Parasitology Department, Theodor Bilharz Research Institute) ;
  • Hammam, Olft (Pathology Department, Theodor Bilharz Research Institute) ;
  • Karim, Amr (Biochemistry Department, Faculty of Science, Ain Shams University) ;
  • Medhat, Amina (Biochemistry Department, Faculty of Science, Ain Shams University) ;
  • Khela, Mamdouh (Biochemistry Department, Theodor Bilharz Research Institute) ;
  • El-Dabaa, Ehab (Biochemistry Department, Theodor Bilharz Research Institute)
  • Received : 2012.10.13
  • Accepted : 2012.12.13
  • Published : 2013.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

This study aimed to evaluate the efficacy of fructose-1,6-bis phosphate aldolase (SMALDO) DNA vaccination against Schistosoma mansoni infection using different routes of injection. The SMALDO has been cloned into the eukaryotic expression vector pcDNA3.1/V5-His TOPO-TA and was used in injecting Swiss albino mice intramuscularly (IM), subcutaneously (SC), or intraperitoneally (IP) ($50{\mu}g/mouse$). Mice vaccinated with non-recombinant pcDNA3.1 served as controls. Each group was immunized 4 times at weeks 0, 2, 4, and 6. Two weeks after the last booster dose, all mice groups were infected with 80 S. mansoni cercariae via tail immersion. At week 8 post-infection, animals were sacrificed for assessment of parasitological and histopathological parameters. High anti-SMALDO IgG antibody titers were detected in sera of all vaccinated groups (P<0.01) compared to the control group. Both the IP and SC vaccination routes resulted in a significant reduction in worm burden (46.2% and 28.9%, respectively, P<0.01). This was accompanied by a significant reduction in hepatic and intestinal egg counts (41.7% and 40.2%, respectively, P<0.01) in the IP group only. The number of dead eggs was significantly increased in both IP and IM groups (P<0.01). IP vaccination recorded the highest significant reduction in granuloma number and diameter (54.7% and 29.2%, respectively, P<0.01) and significant increase in dead miracidia (P<0.01). In conclusion, changing the injection route of SMALDO DNA vaccination significantly influenced the efficacy of vaccination. SMALDO DNA vaccination via IP route could be a promising protective and antipathology vaccine candidate against S. mansoni infection.

Keywords

References

  1. El-Khoby T, Galal N, Fenwick A, Barakat R, El-Hawey A, Nooman Z, Habib M, Abdel-Wahab F, Gaber NS, Hammom HM, Hussein MH, Mikhail NN, Cline BL, Srrickland GT. The epidemiology of schistosomiasis in Egypt: summary findings in nine governorates. Am J Trop Med Hyg 2000; 62: 88-99.
  2. McManus DP, Loukas A. Current status of vaccines for schistosomiasis. Clin Microbiol Rev 2008; 21: 225-242. https://doi.org/10.1128/CMR.00046-07
  3. Richter D, Reynolds SR, Harn DA. Candidate vaccine antigens that stimulate the cellular immune response of mice vaccinated with irradiated cercariae of Schistosoma mansoni. J Immunol 1993; 151: 256-265.
  4. El-Dabaa E, Mei H, El-Sayed A, Karim AM, Eldesoky HM, Fahim FA, LoVerde PT, Saber MA. Cloning and characterization of Schistosoma mansoni fructose-1,6-bisphosphate aldolase isozyme. J Parasitol 1998; 84: 954-960. https://doi.org/10.2307/3284627
  5. Skelly PJ, Stein LD, Shoemaker CB. Expression of Schistosoma mansoni genes involved in anaerobic and oxidative glucose metabolism during the cercariae to adult transformation. Molecular Biochem Parasitol 1993; 60: 93-104. https://doi.org/10.1016/0166-6851(93)90032-S
  6. Mathews CK, Van Hold KE. Biochemistry. Redwood City, California, USA. The Bengamin/Cumming Publishing Company, Inc. 1990, p 433-455.
  7. Rumjanek FK. Biochemistry and physiology. In Rollinson D, AJG Simpson AJG eds, The Biology of Schistosomes. London, UK. Academic Press. 1987, p 163-183.
  8. Harrop R, Coulson PS, Wilson RA. Characterization, cloning and immunogenicity of antigens released by lung-stage larvae of Schistosoma msnoni. Parasitology 1999; 118: 583-594. https://doi.org/10.1017/S003118209900431X
  9. Marques HH, Zouain CS, Torres CBB, Oliveira JS, Alvesb JB, Goes AM. Protective effect and granuloma down-modulation promoted by RP44 antigen a fructose 1,6 bisphosphate aldolase of Schistosoma mansoni. Immunobiology 2008; 213: 437-446. https://doi.org/10.1016/j.imbio.2007.10.002
  10. Capron A, Riveau GJ, Bartley PB, McManus DP. Prospects for a schistosome vaccine. Curr Drug Targets Immune Endocr Metabol Disord 2002; 2: 281-290. https://doi.org/10.2174/1568008023340587
  11. Melkebeek V, Sonck E, Verdonck F, Goddeeris BM, Cox E. Optimized FaeG expression and a thermolabile enterotoxin DNA adjuvant enhance priming of an intestinal immune response by an FaeG DNA vaccine in pigs. Clin Vaccine Immunol 2007; 14: 28-35. https://doi.org/10.1128/CVI.00268-06
  12. Wei F, Liu Q, Zhai Y, Fu Z, Liu W, Shang L, Men J, Gao S, Lian H, Jin H, Chen C, Lin J, Shi Y, Xia Z, Zhu XQ. IL-18 enhances protective effect in mice immunized with a Schistosoma japonicum FABP DNA vaccine. Acta Trop 2009; 3: 284-288.
  13. Zhu Y, Lu F, Dai Y, Wang X, Tang J, Zhao S, Zhang C, Zhang H, Lu S, Wang S. Synergistic enhancement of immunogenicity and protection in mice against Schistosoma japonicum with codon optimization and electroporation delivery of SjTPI DNA vaccines. Vaccine 2010; 28: 5347-5355. https://doi.org/10.1016/j.vaccine.2010.05.017
  14. Ahmed H, Romeih M, Abou Shousha T. DNA Immunization with the gene encoding Sm21.7 protein protects mice against Schistosoma mansoni infections. J Am Sci 2006; 2: 59-69.
  15. Romeih MH, Hassan HM, Shousha TS, Saber MA. Immunization against Egyptian Schistosoma mansoni infection by multivalent DNA vaccine. Acta Biochim Biophys Sin (Shanghai) 2008; 40: 327-338. https://doi.org/10.1111/j.1745-7270.2008.00404.x
  16. Nessim N, Hassan S, William S, el-Baz H. Effect of the broad spectrum antihelmintic drug flubendazole upon Schistosoma mansoni experimentally infected mice. Arzneimittelforschung 2000; 50: 1129-1113.
  17. Innis MA, Gelfand DH, Sninsky JJ, White TJ. PCR Protocols. A Guide to Methods and Applications. San Diego, California, USA. Academic Press. 1990; p 4-36.
  18. Shuman S. Novel approach to molecular cloning and polynucleotide synthesis using vaccinia DNA topoisomerase. J Biol Chem 1994; 269: 32678-32684.
  19. Sambrook J, Russell DW. Molecular Cloning: A Laboratory Manual. 3rd ed. N Y., USA. Cold Spring Harbor Laboratory Press. 2001.
  20. Shalaby KA, Yin L, Thakur A, Christen L, Niles EG, LoVerde PT. Protection against Schistosoma mansoni utilizing DNA vaccination with genes encoding Cu/Zn cytosolic superoxide dismutase, signal peptide-containing superoxide dismutase and glutathione peroxidase enzymes. Vaccine 2003; 22: 130-136. https://doi.org/10.1016/S0264-410X(03)00535-8
  21. Hillyer GV, Gomez de Rios I. The enzyme-linked immunosorbent assay (ELISA) for the immunodiagnosis of schistosomiasis. Am J Trop Med Hyg 1979; 28: 237-241.
  22. Duvall R, DeWitt W. An improved perfusion technique for recovering adult schistosomes from laboratory animals. Am J Trop Med Hyg 1967; 6: 483-486.
  23. Kamel I, Cheever A, Elwi A, Mosimann JE, Danner R. Schistosoma mansoni and Schistosoma haematobium infections in Egypt. I. Evaluation of techniques for recovery of worms and eggs at necropsy. Am J Trop Med Hyg 1977; 26: 696-701.
  24. Pellegrino J, Oliveira CA, Faria J. New approach to the screening of drugs in experimental schistosomiasis mansoni in mice. Am J Trop Med Hyg 1962; 11: 201-215.
  25. von Lichtenberg FC. Host response to eggs of Schistosoma mansoni. I. Granuloma formation in the sensitized laboratory mouse. Am J Pathol 1962; 41: 711-731.
  26. Coban C, Kobiyama K, Aoshi T, Takeshita F, Horii T, Akira S, Ishii KJ. Novel strategies to improve DNA vaccine immunogenicity. Curr Gene Ther 2011; 11: 479-484. https://doi.org/10.2174/156652311798192815
  27. Kozak M. An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res 1987; 15: 8125-8148. https://doi.org/10.1093/nar/15.20.8125
  28. Cherif MS, Shuaibu MN, Kurosaki T. Immunogenicity of novel nanoparticle-coated MSP-1 C-terminus malaria DNA vaccine using different routes of administration. Vaccine 2011; 29: 9038-9050. https://doi.org/10.1016/j.vaccine.2011.09.031
  29. Kedzierska K, Curtis JM, Valkenburg SA, Hatton LA, Kiu H, Doherty PC, Kedzierski L. Induction of protective $CD4^+$ T cell-mediated immunity by a Leishmania peptide delivered in recombinant influenza viruses. PLoS One 2012; 7: e33161. https://doi.org/10.1371/journal.pone.0033161
  30. Lundstrom K. Alphavirus-based vaccines. Curr Opin Mol Ther 2002; 4: 28-34.
  31. Zhu Y, Ren J, Da'dara A, Harn D, Xu, M, Si J, Yu C, Liang Y, Ye P, Yin X, He W, Xu Y, Cao G, Hua W. The protective effect of a Schistosoma japonicum Chinese strain 23 kDa plasmid DNA vaccine in pigs is enhanced with IL-12. Vaccine 2004; 23: 78-83. https://doi.org/10.1016/j.vaccine.2004.04.031
  32. Wynn TA, Cheever AW, Jankovic D, Poindexter RW, Caspar P, Lewis FA, Sher A. An IL-12 based vaccination method for preventing fibrosis induced by schistosome infection. Nature 1995; 376: 594-596. https://doi.org/10.1038/376594a0
  33. Hoffmann KF, Caspar P, Cheever AW, Wynn TA. INF-gamma, IL-12 and TNF-alpha are required to maintain reduced liver pathology in mice vaccinated with Schistosoma mansoni eggs and IL-12. J Immunol 1998; 161: 4201-4210.
  34. Pearce EJ, Vasconcelos JP, Brunet LR, Sabin EA. IL-4 in schistosomiasis. Exp Parasitol 1996; 84: 295-299. https://doi.org/10.1006/expr.1996.0116
  35. Eberl M, Beck E, Coulson CP, Okamura H, Wilson WR, Mountford MA. IL-18 potentiates the adjuvant properties of IL-12 in the induction of a strong Th1 type immune response against a recombinant antigen. Vaccine 2000; 18: 2002-2008. https://doi.org/10.1016/S0264-410X(99)00532-0

Cited by

  1. Protein extract from head-foot tissue of Oncomelania hupensis promotes the growth and development of mother sporocysts of Schistosoma japonicum via upregulation of parasite aldolase gene vol.118, pp.6, 2019, https://doi.org/10.1007/s00436-019-06308-8
  2. Why Do Intravascular Schistosomes Coat Themselves in Glycolytic Enzymes? vol.41, pp.12, 2013, https://doi.org/10.1002/bies.201900103
  3. Comparative study of excretory-secretory proteins released by Schistosoma mansoni-resistant, susceptible and naïve Biomphalaria glabrata vol.12, pp.1, 2013, https://doi.org/10.1186/s13071-019-3708-0
  4. Amelioration of type 1 diabetes by recombinant fructose-1,6-bisphosphate aldolase and cystatin derived from Schistosoma japonicum in a murine model vol.119, pp.1, 2013, https://doi.org/10.1007/s00436-019-06511-7
  5. Linking murine resistance to secondary cystic echinococcosis with antibody responses targeting Echinococcus granulosus tegumental antigens vol.225, pp.3, 2013, https://doi.org/10.1016/j.imbio.2020.151916
  6. Multifunctional Fructose 1,6-Bisphosphate Aldolase as a Therapeutic Target vol.8, pp.None, 2021, https://doi.org/10.3389/fmolb.2021.719678
  7. Characterization of Fructose-1,6-Bisphosphate Aldolase 1 of Echinococcus multilocularis vol.9, pp.1, 2022, https://doi.org/10.3390/vetsci9010004